POTASSIUM CHLORIDE 20MEQ (potassium chloride)
Potassium Chloride extended-release tablets help patients with low blood potassium levels, a condition known as hypokalemia. This medication treats hypokalemia both with and without metabolic alkalosis, especially when dietary changes or adjusting diuretic medications are not enough to correct the deficiency. It is used to both resolve existing low potassium and prevent it from occurring in at-risk patients.
How POTASSIUM CHLORIDE 20MEQ Works
This medication works by supplying potassium ions, which are essential for maintaining intracellular tonicity and normal renal function. These ions also facilitate the transmission of nerve impulses and the contraction of cardiac, skeletal, and smooth muscles. By providing these ions, the drug helps maintain the necessary concentration gradient between the inside of cells and the blood plasma.
Details
- Status
- Prescription
- First Approved
- 2020-09-09
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
POTASSIUM CHLORIDE 20MEQ Approval History
What POTASSIUM CHLORIDE 20MEQ Treats
2 indicationsPOTASSIUM CHLORIDE 20MEQ is approved for 2 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypokalemia
- Metabolic Alkalosis
POTASSIUM CHLORIDE 20MEQ Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to POTASSIUM CHLORIDE 20MEQ
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
8 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07238400 CARDAMOM | 2025P001799 R01HL181150 | Ph 2 | recruiting | Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia |
| NCT04316611 POTACREH | APHP180577 2019-002544-24 | Ph 2 | withdrawn | Potassium Chloride in Out-of-hospital Cardiac Arrest Due to Refractory Ventricular Fibrillation |
| NCT02450773 | 201501157 | Ph 2 | withdrawn | Prevention of Severe Postpartum Hypertension |
| NCT03627130 NITRATE-CIN | 18/1 | Ph 2 | completed | The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy |
| NCT03483051 PULSE-AS results posted | 828994 | Ph 2 | completed | Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS) |
| NCT01074918 | 012007-080 | Ph 1, Ph 2 | withdrawn | Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients |
| NCT01818583 | AK-01 | Ph 4 | completed | Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter |
| NCT01085071 GRIP-COMPASS | GRIP-COMPASS trial | Ph 4 | completed | Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
POTASSIUM CHLORIDE 20MEQ FDA Label Details
Indications & Usage
POTASSIUM CHLORIDE 20MEQ is indicated for the treatment of Hypokalemia; Metabolic Alkalosis.
Track POTASSIUM CHLORIDE 20MEQ with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.